Marzieh Matin, Ali Asilian, Samaneh Mozafar Poor, Elaheh Haftbaradaran* and Amir Feily
Benign Cutaneous Lymphoid Hyperplasia (CLH) is a B-cell pseudolymphoma of an unknown origin. The face is the most affected site in CLH. This report presents the cases of 3 patients with CLH who were treated with rituximab.
It is a hypothesis that rituximab is useful for treating resistant-to-relapsing forms of CLH that do not respond to previous therapies but must be checked with appropriate designs research.
